Sei Investments Co. Boosts Position in LeMaitre Vascular, Inc. $LMAT

Sei Investments Co. boosted its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 30.7% in the first quarter, HoldingsChannel reports. The institutional investor owned 136,674 shares of the medical instruments supplier’s stock after purchasing an additional 32,128 shares during the period. Sei Investments Co.’s holdings in LeMaitre Vascular were worth $14,922,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in LMAT. Royal Bank of Canada grew its stake in LeMaitre Vascular by 1.5% in the 1st quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock worth $9,579,000 after acquiring an additional 1,735 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of LeMaitre Vascular by 36.4% during the first quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock valued at $2,339,000 after acquiring an additional 7,445 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of LeMaitre Vascular by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock valued at $1,013,000 after acquiring an additional 539 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of LeMaitre Vascular by 119.8% in the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after purchasing an additional 115,141 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of LeMaitre Vascular by 27.0% in the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after purchasing an additional 55,804 shares during the period. 84.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on LMAT. Citizens Jmp raised their price objective on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Weiss Ratings cut LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, June 30th. Barrington Research reissued an “outperform” rating and set a $120.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, June 3rd. Wells Fargo & Company raised their price target on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Finally, Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $112.60.

Insider Transactions at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 5,044 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $111.10, for a total transaction of $560,388.40. Following the completion of the sale, the director directly owned 3,942 shares in the company, valued at $437,956.20. This represents a 56.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO George W. Lemaitre sold 27,881 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the sale, the chief executive officer owned 1,430,019 shares of the company’s stock, valued at $155,428,765.11. This trade represents a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 54,453 shares of company stock valued at $5,906,174. Corporate insiders own 7.40% of the company’s stock.

LeMaitre Vascular Stock Performance

Shares of LMAT stock opened at $102.19 on Friday. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of 37.71, a PEG ratio of 2.88 and a beta of 0.52. The company’s 50 day moving average is $97.08 and its 200 day moving average is $99.63. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. LeMaitre Vascular, Inc. has a 52-week low of $79.00 and a 52-week high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. The company had revenue of $66.55 million during the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.LeMaitre Vascular’s revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.48 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 3 EPS for the current fiscal year.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.